Lilly’s Solanezumab Reaches End Of Road As Donanemab Stays On Development Path
Last Study Of Soluble Amyloid-Clearing Antibody Fails
Executive Summary
Solanezumab did not reduce the risk of progression in preclinical Alzheimer’s disease in the Phase III A4 study but it provided evidence that removing amyloid plaques – the mechanism of action for Lilly’s two remaining Phase III AD therapies, donanemab and remternetug – may be the key to efficacy.